Derazantinib
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205946

CAS#: 1234356-69-4

Description: Derazantinib, also known as ARQ-087, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor ARQ 087 binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.


Chemical Structure

img
Derazantinib
CAS# 1234356-69-4

Theoretical Analysis

MedKoo Cat#: 205946
Name: Derazantinib
CAS#: 1234356-69-4
Chemical Formula: C29H29FN4O
Exact Mass: 468.2325
Molecular Weight: 468.5764
Elemental Analysis: C, 74.34; H, 6.24; F, 4.05; N, 11.96; O, 3.41

Price and Availability

Size Price Availability Quantity
5.0mg USD 190.0 Same day
10.0mg USD 350.0 Same day
25.0mg USD 650.0 Same day
50.0mg USD 1150.0 Same day
100.0mg USD 1750.0 Same day
200.0mg USD 2450.0 Same day
500.0mg USD 3250.0 Same day
1.0g USD 4250.0 2 Weeks
2.0g USD 6950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: ARQ 087; ARQ087; ARQ-087; Derazantinib

IUPAC/Chemical Name: (6R)-6-(2-fluorophenyl)-N-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine

InChi Key: KPJDVVCDVBFRMU-AREMUKBSSA-N

InChi Code: InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1

SMILES Code: COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Derazantinib (ARQ-087) is an inhibitor of the fibroblast growth factor receptor (FGFR) with IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3.
In vitro activity: FGFR pathway inhibition was examined in three solid tumor lines, the colorectal cancer cell line (NCI-H716), and gastric cancer cell lines (SNU-16 and KATO-III). As shown in Fig 3A, ARQ 087 inhibited the phosphorylation of FGFRs in all three cell lines. The mechanism by which ARQ 087 inhibits the growth of FGFR kinase dependent cell lines was also investigated. Treatment with ARQ 087 led to an accumulation of cells in the G1 phase cell cycle in a dose- and time-dependent manner (Fig 4A and Table 4). The sub-G1 population (Fig 4A) of NCI-H716 cells, increased after treatment with 1 μM of ARQ 087 (Fig 4A and Table 4). To investigate whether the disruption of the cell cycle correlated with an increase in apoptosis SNU-16 cells were treated with 1 μM of ARQ 087 for 0, 24, 48, and 72 hours, and X-linked inhibitor of apoptosis protein (XIAP), cleaved PARP, activated caspase 3, phospho-p53 were assessed by Western blotting analysis. A decrease in XIAP, and an increase in cleaved-PARP, activated-caspase 3, and pP53 were observed (Fig 4B). Taken together, these data suggest that ARQ 087 inhibits the proliferation of FGFR amplified cells by inducing G1 cell cycle arrest and apoptosis. Reference: PLoS One. 2016 Sep 14;11(9):e0162594. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023172/
In vivo activity: The in vivo anti-tumor effect of ARQ 087 was assessed in athymic mice bearing Ba/F3-FGFR2, Ba/F3-INSR, SNU-16, and NCI-H716 cell line-derived tumors. ARQ 087 demonstrated potent tumor growth inhibition in the Ba/F3-FGFR2 model, while failing to inhibit the growth of the Ba/F3-INSR model (Fig 6A and 6B). Meaningful (>50 TGI vs. control) tumor inhibition was observed both cancer cell line derived xenograft models. In the SNU-16 xenograft study, treatment with 75 mg/kg and 50 mg/kg achieved 83% (p = 0.002) and 69% (p = 0.013) TGI, respectively (Fig 6C). Partial (PR) and complete (CR) regressions also were observed in both dose groups. In the NCI-H716 human cecum model, 50 mg/kg and 75 mg/kg on a Q1Dx14 schedule demonstrated significant TGI of 68% (p = 0.0001) and 96% (p = 0.0001), respectively (Fig 6D). Reference: PLoS One. 2016 Sep 14;11(9):e0162594. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023172/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 47.67 101.73
DMF 30.0 64.02
DMF:PBS (pH 7.2) (1:3) 0.25 0.53

Preparing Stock Solutions

The following data is based on the product molecular weight 468.5764 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G. Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594. PMID: 27627808; PMCID: PMC5023172.
In vitro protocol: 1. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G. Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594. PMID: 27627808; PMCID: PMC5023172.
In vivo protocol: 1. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G. Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594. PMID: 27627808; PMCID: PMC5023172.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Rossi LD, Vasconcelos GC, Saliba GR, Magalhães Lde C, Soares AM, Cordeiro SS, Amorim RH. [Reliability of functional vision assessment in children with low vision from 2 to 6 years old--searching for evidences]. Arq Bras Oftalmol. 2012 Jul-Aug;75(4):259-63. Portuguese. PubMed PMID: 23258657.

2: Ganguli D, Das N, Saha I, Sanapala KR, Chaudhuri D, Ghosh S, Dey S. Association between inflammatory markers and cardiovascular risk factors in women from Kolkata, W.B, India. Arq Bras Cardiol. 2011 Jan;96(1):38-46. Epub 2010 Dec 22. English, Portuguese, Spanish. PubMed PMID: 21180893.

3: Castinheiras-Neto AG, Costa-Filho IR, Farinatti PT. [Cardiovascular responses to resistance exercise are affected by workload and intervals between sets]. Arq Bras Cardiol. 2010 Oct;95(4):493-501. Multiple languages. PubMed PMID: 21180785.

4: Castinheiras-Neto AG, Costa-Filho IR, Farinatti PT. [Cardiovascular responses to resistance exercise are affected by workload and intervals between sets.]. Arq Bras Cardiol. 2010 Sep 3. pii: S0066-782X2010005000119. [Epub ahead of print] Portuguese. PubMed PMID: 20802962.

5: Dantas RO, Alves LM, Cassiani Rde A. Gender differences in proximal esophageal contractions. Arq Gastroenterol. 2009 Oct-Dec;46(4):284-7. PubMed PMID: 20232007.

6: Gonçalves AA, Cardão FL, Soares MG, Weksler A, Weksler C, Tura BR, da Silva PR, da Rocha AS. Predictive value of angina to detect coronary artery disease in patients with severe aortic stenosis aged 50 years or older. Arq Bras Cardiol. 2006 Dec;87(6):701-4. English, Portuguese. PubMed PMID: 17262106.



Additional Information